Literature DB >> 25869391

ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Keith D Lindor1, Kris V Kowdley2, M Edwyn Harrison3.   

Abstract

Primary sclerosing cholangitis is a chronic cholestatic liver disease that can shorten life and may require liver transplantation. The cause is unknown, although it is commonly associated with colitis. There is no approved or proven therapy, although ursodeoxycholic acid is used by many on an empiric basis. Complications including portal hypertension, fat-soluble vitamin deficiency, metabolic bone diseases, and development of cancers of the bile duct or colon can occur.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25869391     DOI： 10.1038/ajg.2015.112

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


  148 in total

Review 1.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

2.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Authors:  Espen Melum; Andre Franke; Christoph Schramm; Tobias J Weismüller; Daniel Nils Gotthardt; Felix A Offner; Brian D Juran; Jon K Laerdahl; Verena Labi; Einar Björnsson; Rinse K Weersma; Liesbet Henckaerts; Andreas Teufel; Christian Rust; Eva Ellinghaus; Tobias Balschun; Kirsten Muri Boberg; David Ellinghaus; Annika Bergquist; Peter Sauer; Euijung Ryu; Johannes Roksund Hov; Jochen Wedemeyer; Björn Lindkvist; Michael Wittig; Robert J Porte; Kristian Holm; Christian Gieger; H-Erich Wichmann; Pieter Stokkers; Cyriel Y Ponsioen; Heiko Runz; Adolf Stiehl; Cisca Wijmenga; Martina Sterneck; Severine Vermeire; Ulrich Beuers; Andreas Villunger; Erik Schrumpf; Konstantinos N Lazaridis; Michael P Manns; Stefan Schreiber; Tom H Karlsen
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

Review 3.  Pathogenesis and management of pruritus in cholestatic liver disease.

Authors:  Mohamad H Imam; Andrea A Gossard; Emmanouil Sinakos; Keith D Lindor
Journal:  J Gastroenterol Hepatol       Date:  2012-07       Impact factor: 4.029

4.  Bone disease in patients with primary sclerosing cholangitis.

Authors:  Paul Angulo; Garfield A Grandison; Derek G Fong; Jill C Keach; Keith D Lindor; Einar Bjornsson; Alvaro Koch
Journal:  Gastroenterology       Date:  2010-10-16       Impact factor: 22.682

5.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

6.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

7.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.

Authors:  T A Knox; M M Kaplan
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

Review 8.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

9.  Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.

Authors:  Roman Zenouzi; Tobias J Weismüller; Peter Hübener; Kornelius Schulze; Michael Bubenheim; Nadine Pannicke; Christina Weiler-Normann; Henrike Lenzen; Michael P Manns; Ansgar W Lohse; Christoph Schramm
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

10.  Methotrexate therapy for primary biliary cirrhosis.

Authors:  Nancy Bach; Carol Bodian; Henry Bodenheimer; Edward Croen; Paul D Berk; Swan N Thung; Keith D Lindor; Thierry Therneau; Fenton Schaffner
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864
View more
  101 in total

Review 1.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

Review 2.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

3.  Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.

Authors:  Nikita Joshi; Anna K Kopec; Holly Cline-Fedewa; James P Luyendyk
Journal:  Toxicology       Date:  2016-12-31       Impact factor: 4.221

Review 4.  Large-duct cholangiopathies: aetiology, diagnosis and treatment.

Authors:  Shyam Menon; Andrew Holt
Journal:  Frontline Gastroenterol       Date:  2019-01-04

5.  Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.

Authors:  De-Jun Cui; Xun Zhao; Mei Hu
Journal:  Am J Gastroenterol       Date:  2017-01       Impact factor: 10.864

6.  The 2016 diagnostic criteria for primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Kenji Notohara; Susumu Tazuma; Atsushi Tanaka; Hiroyuki Isayama; Toshio Tsuyuguchi; Toshiyuki Mori; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2016-12-05       Impact factor: 7.527

Review 7.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

8.  Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis.

Authors:  Laetitia Nguyen; Nora Cazzagon; Christophe Corpechot; Sanaâ El Mouhadi; Sara Lemoinne; Olivier Chazouillères; Lionel Arrivé
Journal:  Eur Radiol       Date:  2018-08-29       Impact factor: 5.315

9.  Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Atta Nawabi; Timothy Schmitt; Rance Nault; Timothy R Zacharewski; Cheryl E Rockwell; Matthew J Flick; James P Luyendyk
Journal:  Blood       Date:  2016-02-26       Impact factor: 22.113

Review 10.  [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Authors:  S Hohenester; U Beuers
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.